REFERENCES: 1. Data on file. Johnson & Johnson. 2. XARELTO® [prescribing information]. Titusville, NJ: Johnson & Johnson. 3. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775. 4. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. 5. Mega JL, Braunwald E, Wiviott SD, et al. N Engl J Med. 2012;366(1):9-19. 6. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial
fibrillation. N Engl J Med. 2011;365(10):883-891. 7. EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. 8. Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513-523. 9. Cappato R, Ezekowitz MD, Klein AL, et al. Eur Heart J. 2014;35(47):3346-3355. 10. Cappato R, Marchlinski FE, Hohnloser SH, et al. Eur Heart
J. 2015;36(28):1805-1811. 11. Gibson CM, Mehran R, Bode C, et al. N Engl J Med. 2016;375(25):2423-2434. 12. Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-1330. 13. Weitz JI, Lensing AWA, Prins MH, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376(13):1211-1222. 14. Ohman EM, Roe MT, Steg PG, et al. Lancet. 2017;389(10081):1799-1808. 15. Frank Peacock W, Coleman CI, Diercks DB, et al. Emergency department discharge of pulmonary embolus patients. Acad Emerg Med.
2018;25(9):995-1003. 16. Hart RG, Sharma M, Mundl H, et al. N Engl J Med. 2018;378(23):2191-2201. 17. Spyropoulos AC, Ageno W, Albers GW, et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N Engl J Med. 2018;379(12):1118-1127. 18. Zannad F, Anker SD, Byra WM, et al. N Engl J Med. 2018;379(14):1332-1342. 19. Dangas GD, Tijssen JGP, Wöhrle J, et al. N Engl J Med. 2020;382(2):120-129. 20. Spyropoulos AC, Lipardi C, Xu J, et al. Improved benefit risk profile of rivaroxaban in a subpopulation of the MAGELLAN study. Clin Appl Thromb Hemost. 2019;25:1076029619886022. 21. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31-39. 22. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786. 23. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994-2004. 24. McCrindle BW, Michelson AD, Van Bergen AH, et al; UNIVERSE Study Investigators. Thromboprophylaxis for children post-Fontan procedure: insights from the UNIVERSE study. J Am Heart Assoc. 2021;10(24):e021765. 25. Male C, Lensing AWA, Palumbo JS, et al; EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18-e27. 26. Lensing AWA, Male C, Young G, et al. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thromb J. 2018;16:34.